▶ FOLLISTATIN-344 · SUBTOPIC · DOSING LITERATURE
FOLLISTATIN-344 Dosing Literature
For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.
SCOPE OF THIS PAGE
This page documents the published-literature dose ranges that appear in trials and animal studies of FOLLISTATIN-344. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.
ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH
The published research record for FOLLISTATIN-344 reports the following route(s) of administration: Subcutaneous (research), Intramuscular (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of FOLLISTATIN-344.
PHARMACOKINETIC HALF-LIFE
Published pharmacokinetic data report a half-life for FOLLISTATIN-344 of approximately Several days (long-acting in animal models). Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.
CITED DOSE RANGES IN THE LITERATURE
The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of FOLLISTATIN-344. Refer to the original publication for full protocol detail.
- Lee SJ, Lee YS, Zimmers TA, et al. (2010) reports the FOLLISTATIN-344 protocol used in Regulation of muscle mass by follistatin and activins, published in Mol Endocrinol. PMID 20801891. See the source for the protocol-level dose range, frequency, and duration. link
- Kota J, Handy CR, Haidet AM, et al. (2009) reports the FOLLISTATIN-344 protocol used in Follistatin gene delivery enhances muscle growth and strength in nonhuman primates, published in Sci Transl Med. PMID 20371475. See the source for the protocol-level dose range, frequency, and duration. link
DOSING Q+A FROM LITERATURE
The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.
▶ What are the side effects?
Limited published human safety data. Theoretical risks include off-target activin pathway inhibition (HPG-axis disruption from activin antagonism), and injection-site reactions. Animal-model evidence indicates greater safety than direct anti-myostatin antibodies, which have produced cardiac and HPG side effects in clinical trials.
▶ How is follistatin-344 dosed in research?
Animal-model research uses variable subcutaneous and intramuscular dosing. Human-equivalent dosing is not established. This wiki does not recommend any human dose.
STORAGE OF THE REFERENCE COMPOUND
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C, 14-28 days
Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.
RECONSTITUTION MATH (CALCULATOR)
The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.
REGULATORY CONTEXT
FDA · Not FDA-approved. Investigational compound. Research-use only.
WADA · Prohibited at all times under WADA Section S2 (Growth Factors and Myostatin Antagonists sub-category).
RELATED PAGES
▶ LAST UPDATED · 2026-05-25